Considerations on discontinuing natalizumab for the treatment of multiple sclerosis

Publikation: Beitrag in Fachzeitschrift › Kurzartikel (Letter) / Leserbrief mit Originaldaten › Beigetragen › Begutachtung

Beitragende

Joseph R. Berger - , University of Kentucky (Autor:in)
Diego Centonze - , University of Rome Tor Vergata (Autor:in)
Giancarlo Comi - , Vita-Salute San Raffaele University (Autor:in)
Christian Confavreux - , Hôpital neurologique et neurochirurgical Pierre Wertheimer (Autor:in)
Gary Cutter - , University of Alabama at Birmingham (Autor:in)
Gavin Giovannoni - , Barts Health NHS Trust (Autor:in)
Ralf Gold - , Ruhr-Universität Bochum (Autor:in)
Hans Peter Hartung - , Heinrich Heine Universität Düsseldorf (Autor:in)
Fred Lublin - , Icahn School of Medicine at Mount Sinai (Autor:in)
Augusto Miravalle - , University of Colorado Denver (Autor:in)
Xavier Montalban - , Autonomous University of Barcelona (Autor:in)
Paul O'Connor - , University of Toronto (Autor:in)
Tomas Olsson - , Karolinska Institutet (Autor:in)
Chris H. Polman - , Vrije Universiteit Amsterdam (VU) (Autor:in)
Olaf Stuve - , University of Texas Southwestern Medical Center (Autor:in)
Jerry S. Wolinsky - , University of Texas Health Science Center at Houston (Autor:in)
Tjalf Ziemssen - , Klinik und Poliklinik für Neurologie (Autor:in)

PubMed	20818795